title: [Efficacy of combination therapy for multiple liver metastases of colorectal cancer].
abstract: In our hospital, combination therapy, mainly intra-arterial infusion, is performed for multiple liver metastases of colorectal cancer. The median survival time of the combination group (n = 18), the hepatectomy only group (n = 3) and the best supportive care group (n = 7) were 21.7, 12.5 and 6.1 months, respectively. The prognosis of the combination group was significantly better than that in the other groups (p < 0.0001). Univariate analysis against the combination group revealed that serum CEA was a significant prognostic factor (p = 0.0196). Moreover, we divided the combination group into two groups on the basis of serum CEA either below or above 50 ng/ml. The prognosis of the low CEA group (n = 11), whose median survival time was 25.9 months, was significantly better than the high CEA group (n = 7), whose median survival time was 17.8 months (p = 0.0031). It therefore appears that combination therapy may be of no benefit when serum CEA is above 50 ng/ml.
authors.affiliation: Dept. of Surgery, Osaka National Hospital.
authors.forename: Y
authors.initials: Y
authors.lastname: Kurokawa
authors.forename: Y
authors.initials: Y
authors.lastname: Hasuike
authors.forename: H
authors.initials: H
authors.lastname: Mishima
authors.forename: Y
authors.initials: Y
authors.lastname: Takeda
authors.forename: K
authors.initials: K
authors.lastname: Fujitani
authors.forename: E
authors.initials: E
authors.lastname: Shin
authors.forename: T
authors.initials: T
authors.lastname: Sawamura
authors.forename: I
authors.initials: I
authors.lastname: Nishisho
authors.forename: T
authors.initials: T
authors.lastname: Tsujinaka
authors.forename: N
authors.initials: N
authors.lastname: Kikkawa
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D002272:Carcinoembryonic Antigen / Q000097:blood; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery*; D008297:Male; D012189:Retrospective Studies; D016019:Survival Analysis
chemical_list: D000964:Antimetabolites, Antineoplastic; D002272:Carcinoembryonic Antigen; D005472:Fluorouracil